Table 1.
Variable | Patient 1 | Patient 2 |
---|---|---|
Age, y | 51 | 63 |
Sex | M | M |
BMI, kg/m2 | 22 | 18 |
Race | AA | AA |
Symptoms at presentation | ||
Fever | No | No |
Dyspnea | Yes | Yes |
Cough | No | Yes |
Nausea/emesis | Yes | No |
Myalgias | Yes | No |
Vital signs baseline (peak) | ||
Temp | 98.8 (100.8) | 98.3 (98.7) |
RR, per min | 17 (25) | 17 (20) |
HR, per min | 66 (99) | 94 (110) |
Oxygen Saturation | 86 (85) | 90 (90) |
SBP, mm Hg | 153 (180) | 130 (143) |
Baseline (peak) lab. values | ||
WBC, ×109/L | 5.1 (11) | 2.4 (5.7) |
Lymphocytes, ×109/L | 18 | 34 (49) |
Hemoglobin, g/dL | 12.7 (12.9) | 12.8 (13) |
Platelets, ×109/L | 88 (155) | 454 (459) |
AST, units/L | 108 (131) | 53 |
ALT, units/L | 78 (84) | 43 |
ALP, IU/L | 135 (135) | 92 |
BUN, mg/dL | 11 (24) | 33 |
Creatinine, mg/dL | 0.8 (0.9) | 1.6 |
CRP, mg/L | … | 4.95 (4.95) |
ESR, h | … | 131 (131) |
Ferritin, ng/mL | 742 (1264) | 2292 (2292) |
Superimposed infection | Streptococcus pneumoniae | None |
HAART regimen | None | None |
Immunological profile | ||
CD4 cell count | 10.2 | 116.3 |
HIV RNA PCR copies | 26 900 | 2 540 000 |
Management | ||
Hydroxychloroquine | NA | NA |
Corticosteroids | NA | NA |
Tocilizumab | NA | NA |
Antibiotics | Azithromycin, bactrim, zosyn | Bactrim |
Other | … | Zinc sulfate, vitamin C |
Outcomes | ||
Length of hospitalization, d | 10 | 7 |
ICU admission, n (%) | 0 (0) | 0 (0) |
Mechanical ventilation, n (%) | 0 (0) | 0 (0) |
In‐hospital death, n (%) | 0 (0) | 0 (0) |
Readmission | 0 (0) | 0 (0) |
Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BMI, Body mass index; BUN, blood urea nitrogen; CD4, cluster of differentiation 4; CRP, C reactive protein; HAART, highly active antiretroviral therapy; HIV RNA PCR, human immunodeficiency virus ribonucleic acid polymerase chain reaction; HR, heart rate; ICU, intensive care unit; RR, respiratory rate; SBP, systolic blood pressure; SR, erythrocyte sedimentation rate; WBC, white blood cell count.